Your browser doesn't support javascript.
loading
Further delineation of the NTHL1 associated syndrome: A report from the French Oncogenetic Consortium.
Boulouard, Flavie; Kasper, Edwige; Buisine, Marie-Pierre; Lienard, Gwendoline; Vasseur, Stéphanie; Manase, Sandrine; Bahuau, Michel; Barouk Simonet, Emmanuelle; Bubien, Virginie; Coulet, Florence; Cusin, Véronica; Dhooge, Marion; Golmard, Lisa; Goussot, Vincent; Hamzaoui, Nadim; Lacaze, Elodie; Lejeune, Sophie; Mauillon, Jacques; Beaumont, Marie-Pascale; Pinson, Stéphane; Tlemsani, Camille; Toulas, Christine; Rey, Jean-Marc; Uhrhammer, Nancy; Bougeard, Gaëlle; Frebourg, Thierry; Houdayer, Claude; Baert-Desurmont, Stéphanie.
Afiliación
  • Boulouard F; Department of Genetics, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Rouen, France.
  • Kasper E; Comprehensive Cancer Center François Baclesse, Laboratory of Cancer Biology and Genetics, Caen, France.
  • Buisine MP; Department of Genetics, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Rouen, France.
  • Lienard G; Department of Biochemistry and Molecular Biology, Lille University Hospital Center, UMR 1277 Inserm-9020 CNRS, Lille University, Lille, France.
  • Vasseur S; Department of Genetics, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Rouen, France.
  • Manase S; Department of Genetics, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Rouen, France.
  • Bahuau M; Department of Genetics, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Rouen, France.
  • Barouk Simonet E; Medical genetics Department, Henri Mondor Hospital, Créteil, France.
  • Bubien V; Cancer Genetics Unit, Institut Bergonie, Bordeaux, France.
  • Coulet F; Cancer Genetics Unit, Institut Bergonie, Bordeaux, France.
  • Cusin V; Department of Genetics, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France.
  • Dhooge M; Department of Genetics, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France.
  • Golmard L; Gastroenterology Unit, Cochin University Hospital, Paris Descartes University, Paris, France.
  • Goussot V; Institut Curie, Department of Genetics and Paris Sciences, Lettres Research University, Paris, France.
  • Hamzaoui N; Department of Tumor Biology and Pathology, Georges-François Leclerc Center, Dijon, France.
  • Lacaze E; Department of Oncogenetics, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France.
  • Lejeune S; Department of Genetics, Le Havre General Hospital, Normandy Centre for Genomic and Personalized Medicine, Le Havre, France.
  • Mauillon J; Genetic Pathology Biology Department, Lille University Hospital Center, Jeanne de Flandre Hospital, Lille, France.
  • Beaumont MP; Department of Genetics, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Rouen, France.
  • Pinson S; Department of Genetics, Rennes University Hospital Center, Rennes, France.
  • Tlemsani C; Genetics Department, Hospices Civils de LYON (HCL), University Hospital, East Pathology Center, Bron, France.
  • Toulas C; Department of Oncogenetics, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France.
  • Rey JM; Oncogenetic Laboratory, Cancer University Institute Toulouse Oncopole, Toulouse, France.
  • Uhrhammer N; Department of Pathology and Oncobiology, Montpellier University Hospital, Montpellier, France.
  • Bougeard G; Centre Jean Perrin, Oncogenetics and Clermont Auvergne University, INSERM U1240, Clermont-Ferrand, France.
  • Frebourg T; Department of Genetics, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Rouen, France.
  • Houdayer C; Department of Genetics, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Rouen, France.
  • Baert-Desurmont S; Department of Genetics, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Rouen, France.
Clin Genet ; 99(5): 662-672, 2021 05.
Article en En | MEDLINE | ID: mdl-33454955
ABSTRACT
Biallelic pathogenic variants in the NTHL1 (Nth like DNA glycosylase 1) gene cause a recently identified autosomal recessive hereditary cancer syndrome predisposing to adenomatous polyposis and colorectal cancer. Half of biallelic carriers also display multiple colonic or extra-colonic primary tumors, mainly breast, endometrium, urothelium, and brain tumors. Published data designate NTHL1 as an important contributor to hereditary cancers but also underline the scarcity of available informations. Thanks to the French oncogenetic consortium (Groupe Génétique et Cancer), we collected NTHL1 variants from 7765 patients attending for hereditary colorectal cancer or polyposis (n = 3936) or other hereditary cancers (n = 3829). Here, we describe 10 patients with pathogenic biallelic NTHL1 germline variants, that is, the second largest NTHL1 series. All carriers were from the "colorectal cancer or polyposis" series. All nine biallelic carriers who underwent colonoscopy presented adenomatous polyps. For digestive cancers, average age at diagnosis was 56.2 and we reported colorectal, duodenal, caecal, and pancreatic cancers. Extra-digestive malignancies included sarcoma, basal cell carcinoma, breast cancer, urothelial carcinoma, and melanoma. Although tumor risks remain to be precisely defined, these novel data support NTHL1 inclusion in diagnostic panel testing. Colonic surveillance should be conducted based on MUTYH recommendations while extra-colonic surveillance has to be defined.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Ováricas / Síndromes Neoplásicos Hereditarios / Desoxirribonucleasa (Dímero de Pirimidina) Tipo de estudio: Guideline / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Genet Año: 2021 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Ováricas / Síndromes Neoplásicos Hereditarios / Desoxirribonucleasa (Dímero de Pirimidina) Tipo de estudio: Guideline / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Genet Año: 2021 Tipo del documento: Article País de afiliación: Francia